EUVIMEDEUVIMED entdecken
Multizentrische StudieBeobachtungsstudieOpen Access · CC BY 4.0

Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results

Robert C G Martin Ii iD, Rebekah Ruth White iD, Malcolm M Bilimoria iD, Govindarajan Narayanan, Michael D Kluger iD, David A Iannitti iD, Patricio M Polanco, Chet W Hammill iD, Sean P Cleary, Robert Evans Heithaus iD, Theodore Welling, Carlos H F Chan

The Oncologist · 07.10.2026 · 31 (11)

DOI: 10.1093/oncolo/oyag416 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift The Oncologist, online erschienen am 14.10.2026. Verfasst von Robert C G Martin Ii und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY 40202, United States. Hauptthemen laut MEDLINE: Carcinoma, Pancreatic Ductal, Irreversible Electroporation Therapy, Pancreatic Neoplasms. Die Arbeit nennt 24 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Penumbra, Canon Medical, and AngioDynamics.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Irreversible electroporation (IRE) is used in selected patients with Stage III pancreatic ductal adenocarcinoma (PDAC), but its association with survival relative to standard-of-care (SOC) therapy remains uncertain.

Methods

This multicenter observational study included 137 patients from the DIRECT registry: 99 treated within an IRE-based strategy and 38 receiving SOC without IRE. Overall survival (OS) from diagnosis was evaluated using propensity-score overlap weighting as the principal adjusted analysis. Conventional inverse probability of treatment weighting (IPTW), propensity-score matching, 3- and 6-month landmark analyses, and a time-dependent Cox model treating IRE as a time-varying exposure were sensitivity analyses. Restricted mean survival time (RMST) at 24 months was estimated.

Results

Median time from diagnosis to enrollment was 8 months (IQR, 6-10) with IRE and 4 months (IQR, 3-6) with SOC (P < .0001). Unadjusted median OS was 28 months (95% CI, 23-33) and 15 months (95% CI, 12-21), respectively. Overlap weighting was associated with lower mortality with IRE (HR, 0.28; 95% bootstrap CI, 0.12-0.48). Twenty-four-month RMST was 21.22 vs 16.24 months, an absolute difference of 4.99 months (95% bootstrap CI, 1.15-8.12). The time-dependent analysis attenuated but retained the association (HR, 0.59; 95% bootstrap CI, 0.37-0.94). Other sensitivity analyses were directionally consistent.

Conclusions

An IRE-based treatment strategy was associated with longer OS than SOC without IRE. Attenuation in the time-dependent analysis indicates that treatment timing and selection contributed to the observed difference. Given the nonrandomized design and potential residual confounding, these findings demonstrate association rather than an independent causal effect of IRE.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Pancreatic DuctalIrreversible Electroporation TherapyPancreatic NeoplasmsAgedFemaleHumansMaleMiddle AgedNeoplasm StagingRegistries

Stichwörter der Autor:innen

chemotherapy/combination chemotherapygastrointestinal cancers/pancreatic cancerirreversible electroporationsurgical oncology

Autor:innen und Institutionen

  • Division of Surgical Oncology, University of Louisville School of Medicine, Louisville, KY 40202, United States.
  • Moores Cancer Center, University of California, San Diego, La Jolla, CA 92101, United States.
  • Northwest Community Healthcare, Arlington Heights, IL 61312, United States.
  • Miami Cancer Institute, Baptist Health South Florida, Miami, FL 33101, United States.
  • Herbert Irving Comprehensive Cancer Center, Columbia University, New York, NY 10001, United States.
  • Atrium Health Carolinas Medical Center, Charlotte, NC 28201, United States.

ORCID-Profile: Robert C G Martin Ii, Rebekah Ruth White, Malcolm M Bilimoria, Michael D Kluger, David A Iannitti, Chet W Hammill, Robert Evans Heithaus

Förderung

  • Penumbra, Canon Medical, and AngioDynamics

Zitieren

APA

Martin Ii, R. C. G., White, R. R., Bilimoria, M. M., Narayanan, G., Kluger, M. D., Iannitti, D. A., Polanco, P. M., Hammill, C. W., Cleary, S. P., Heithaus, R. E., Welling, T., & Chan, C. H. F. (2026). Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. The Oncologist, 31(11). https://doi.org/10.1093/oncolo/oyag416

Vancouver

Martin Ii RCG, White RR, Bilimoria MM, Narayanan G, Kluger MD, Iannitti DA, et al. Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results. The Oncologist. 2026;31(11). doi:10.1093/oncolo/oyag416

BibTeX
@article{MartinIi2026,
  author = {Martin Ii, Robert C G and White, Rebekah Ruth and Bilimoria, Malcolm M and Narayanan, Govindarajan and Kluger, Michael D and Iannitti, David A and Polanco, Patricio M and Hammill, Chet W and Cleary, Sean P and Heithaus, Robert Evans and Welling, Theodore and Chan, Carlos H F},
  title = {Association of irreversible electroporation treatment with overall survival in Stage III pancreatic ductal adenocarcinoma: DIRECT registry results},
  journal = {The Oncologist},
  year = {2026},
  volume = {31},
  number = {11},
  doi = {10.1093/oncolo/oyag416}
}
Kostenlos starten →